Other grades of this product :
| CP 471,474 Basic information |
| CP 471,474 Chemical Properties |
| Melting point | 135-137°C (dec.) | | density | 1.375±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: ≥20mg/mL | | pka | 9.33±0.50(Predicted) | | form | powder | | color | white to off-white |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 1 |
| CP 471,474 Usage And Synthesis |
| Description | CP 471,474 is a broad-spectrum inhibitor of matrix metalloproteinases (MMPs) with IC50 values of 0.7, 16, 13, and 0.9 nM for MMP-2, MMP-3, MMP-9, and MMP-13, respectively. It is selective for these MMPs over MMP-1 (IC50 = 1,170 nM). CP 471,474 reduces left ventricular enlargement and decreases the incidence of cardiac rupture in mouse models of myocardial infarction when administered at doses of 120 mg/kg twice per day and 240 mg/kg per day, respectively. | | Chemical Properties | White Solid | | Uses | A broad spectrum inhibitor of matrix metalloproteinases that attenuates early left ventricular dilation after experimental myocardial infarction in mice. Studies show that it also inhibits cigarette smoke-induced lung inflammation and the progression of emphysema in guinea pig models. | | Biochem/physiol Actions | CP-471474 is a broad spectrum inhibitor of matrix metalloproteinases. CP-471474 has a low nM IC50 efficacy for MMP-2, MMP-3, MMP-9, and MMP-13. CP-471474 has low potency against MMP-1 (IC50 > 1 uM). CP-471474 prevents left ventricular remodeling after experimental myocardial infarction in mice. CP-471474 also inhibits cigarette smoke-induced lung inflammation and the progression of emphysema in guinea pig models. |
| CP 471,474 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye